

## Responsible Minerals Sourcing

Fresenius Medical Care AG (together with its subsidiaries, “Fresenius Medical Care”) is the world’s leading provider of products and services for individuals with renal disease. With shares listed on the New York Stock Exchange, Fresenius Medical Care is subject to the provisions of Section 13(p) of the United States (“U.S.”) Securities Exchange Act of 1934, as amended (“Securities Exchange Act”) relating to “Conflict Minerals,” and SEC Rule 13p-1 thereunder. Section 13(p) of the Securities Exchange Act and U.S. Securities and Exchange Commission (“SEC”) Rule 13p-1 address the sourcing of the 3TG minerals tin, tantalum, tungsten, and gold necessary to the functionality or production of our products from the Democratic Republic of the Congo and adjoining countries which are known locations where armed groups mine and sell these minerals to finance civil violence. As a company organized in a member state of the European Union (“EU”), Fresenius Medical Care is also subject to Regulation (EU) 2017/821 of the European Parliament and of the Council of 17 May 2017 (“EU Conflict Minerals Regulation”) laying down supply chain due diligence obligations for EU importers of tin, tantalum and tungsten, their ores, and gold originating from conflict-affected and high-risk areas.

Fresenius Medical Care is committed to responsible sourcing, especially as it pertains to conflict minerals and compliance with Securities Exchange Act 13(p), the EU Conflict Minerals Regulation and all other relevant legislation.

As such, Fresenius Medical Care has created a compliance program that includes, but is not limited to:

- membership in cross-industry initiatives,
- supplier engagement, risk mitigation and remediation,
- obtaining relevant information vis-à-vis a reasonable country of origin inquiry (“RCOI”),
- creation of a responsible minerals sourcing program, and
- implementation of due diligence measures that conform with the internationally recognized OECD due diligence framework<sup>1</sup>.

In addition, Fresenius Medical Care publishes a Conflict Minerals Report, which includes, *inter alia*, disclosure of the results of its RCOI and due diligence measures.

For more information regarding Fresenius Medical Care’s compliance program, please contact [cminquiry@freseniusmedicalcare.com](mailto:cminquiry@freseniusmedicalcare.com).

---

<sup>1</sup> OECD. (2016). OECD Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas: Third Edition. Paris: OECD Publishing.